BB Biotech (BION) Q1 2025 earnings summary

Executive summary

• Q1 2025 saw heightened volatility in global markets due to political uncertainty and new US tariffs, impacting biotech sector sentiment and performance.

• BB Biotech reported a net loss of CHF 241 mn for Q1 2025, compared to a net profit of CHF 260 mn in Q1 2024.

• Shareholder return was -8.8% in CHF and -10.3% in EUR, with NAV declining by 10.8% in CHF and 12.3% in EUR, reflecting sector-wide pressures.

• The portfolio was actively managed, with new positions in Akero Therapeutics and exits from Intra-Cellular Therapies, Fate Therapeutics, Sage Therapeutics, and Arvinas.

• AGM approved all proposals, including a CHF 1.80 per share dividend.

Financial highlights

• Market capitalization at period end: CHF 1,692.5 mn (down from CHF 2,368.4 mn in 2023).

• Net Asset Value at period end: CHF 1,944.5 mn (down from CHF 2,323.2 mn in 2023).

• Profit/(loss): CHF -240.9 mn for Q1 2025 (Q1 2024: CHF 75.9 mn profit).

• Closing share price: CHF 30.55 (down from CHF 42.75 in 2023).

• Dividend payout of CHF 1.80 per share in March 2025.

Outlook and guidance

• Management remains cautious amid ongoing policy unpredictability, tight capital markets, and sector volatility.

• Plans to deploy cash reserves selectively to capitalize on attractive valuations, especially in small- and mid-cap biotech.

• Focus on companies with strong balance sheets, differentiated clinical assets, and capital efficiency.

• Regulatory and trade policy shifts are being closely monitored for potential long-term industry impacts.